rs63749930
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000251.3(MSH2):c.1552_1553delCA(p.Gln518ValfsTer10) variant causes a frameshift change. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000251.3 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Lynch syndrome 1 Pathogenic:2
- -
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
not provided Pathogenic:2
The variant results in a shift of the reading frame, and is therefore predicted to result in the loss of a functional protein. Found in at least one symptomatic patient, and not found in general population data. -
Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 10495924, 10564582, 8776590, 18307539, 9611074, 18550572, 10200055, 11304573, 11306449, 14574010, 14961575) -
Hereditary cancer-predisposing syndrome Pathogenic:2
The c.1552_1553delCA pathogenic mutation, located in coding exon 10 of the MSH2 gene, results from a deletion of two nucleotides at nucleotide positions 1552 to 1553, causing a translational frameshift with a predicted alternate stop codon (p.Q518Vfs*10). This alteration has been identified in multiple unrelated patients and families with HNPCC/Lynch syndrome cancers, including colorectal, endometrial, and pancreatic (Nyström-Lahti M et al. Hum. Mol. Genet., 1996 Jun;5:763-9; Cederquist K et al. Int. J. Cancer, 2004 Apr;109:370-6; Yan HL et al. Cancer Sci., 2008 Apr;99:770-80). Of note, this alteration is also designated as c.1550delCA and c.1550_1551delCA in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
This variant deletes 2 nucleotides in exon 10 of the MSH2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been identified in multiple individuals and families affected with Lynch syndrome (PMID: 8776590, 11304573, 11306449, 14961575, 18307539). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Carcinoma of colon Pathogenic:1
The p.Gln518ValfsX10 variant was identified in 14 of 1078 proband chromosomes (frequency: 0.013) from individuals or families with colorectal cancer (Cederquist 2004, Gylling 2008, Nystrom-Lahti 1996, Renkonen 2004, Salahshor 2001, Schweizer 2001, Yan 2008). The variant was also identified in dbSNP (ID: rs63749930) “With Pathogenic allele”, HGMD, COSMIC, “Mismatch Repair Genes Variant Database” and the ClinVar database (classified as a pathogenic variant by the InSiGHT). The p.Gln518ValfsX10 deletion variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 518 and leads to a premature stop codon 10 codons downstream. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the MSH2 gene are an established mechanism of disease in Lynch syndrome and this is the type of variant expected to cause the disorder. In summary, based on the above information, this variant meets our laboratory’s criteria to be classified as pathogenic. -
Lynch syndrome Pathogenic:1
Coding sequence variation introducing premature termination codon -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Gln518Valfs*10) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with hereditary non-polyposis colorectal cancer (PMID: 8776590, 11304573, 11306449, 14961575, 18307539). This variant is also known as MSH2 c.1550_1551delCA. ClinVar contains an entry for this variant (Variation ID: 90697). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at